The Role of Pharmacy Benefit Managers in Access to Biologics for Dermatologic Conditions

In this commentary, we discuss the role of pharmacy benefit managers (PBMs) on access to biologics for patients with psoriasis. We highlight structural and system level barriers to biologics access, as well as how PBMs work as intermediaries between insurers, pharmacies, and drug manufactures to influence prescription formularies and generate health savings. We also discuss how controversial PBM practices such as step therapy, prior authorizations, and spread pricing may limit access to biologics and potentially increase cost for patients. Finally, we highlight how dermatologists and national organizations such as the National Psoriasis Foundation can collaborate and advocate for legislative reforms to increase transparency among PBMs.

Authors

Institutions

Publication Details

Journal
Journal of Psoriasis and Psoriatic Arthritis
Published
2025-10-22
DOI
https://doi.org/10.1177/24755303251387126
Primary Topic
Pharmaceutical studies and practices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Role of Pharmacy Benefit Managers in Access to Biologics for Dermatologic Conditions

Melissa C. Leeolou, Jason Harris, Justin L. Jia, Wilson Liao
Journal of Psoriasis and Psoriatic Arthritis
Pharmaceutical studies and practices
article

The Role of Pharmacy Benefit Managers in Access to Biologics for Dermatologic Conditions

Melissa C. Leeolou, Jason Harris, Justin L. Jia, Wilson Liao
article en

Abstract

In this commentary, we discuss the role of pharmacy benefit managers (PBMs) on access to biologics for patients with psoriasis. We highlight structural and system level barriers to biologics access, as well as how PBMs work as intermediaries between insurers, pharmacies, and drug manufactures to influence prescription formularies and generate health savings. We also discuss how controversial PBM practices such as step therapy, prior authorizations, and spread pricing may limit access to biologics and potentially increase cost for patients. Finally, we highlight how dermatologists and national organizations such as the National Psoriasis Foundation can collaborate and advocate for legislative reforms to increase transparency among PBMs.

Journal of Psoriasis and Psoriatic Arthritis
University of California, San Francisco (US), National Psoriasis Foundation (US), ASIS Foundation (US), Stanford University (US)
Openalex Percentile: Top 57%
Pharmaceutical studies and practices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.